Stablecoin Development Corp (SDEV)
XASE:SDEV
Want to see SDEV full AI Analyst Report?
Top Page
Stablecoin Development Corp
(NYSE MKT:SDEV)
Select Model
Select Model
Rating:38Underperform
Price Target:
$1.50
▼(-49.15% Downside)
Action:DowngradedDate:04/25/26
The score is driven primarily by very weak financial performance (revenue collapse, persistent losses, ongoing cash burn, and deeply negative equity). Technical indicators also point to bearish momentum (below key moving averages with negative MACD). Valuation provides limited support because the company is loss-making and no dividend yield is available.
Positive Factors
Proprietary product/IP
The company owns a proprietary chemistry platform and a marketed product (Avenova) with both consumer and eye‑care professional channels. This entrenched product/IP and multi‑channel go‑to‑market provide durable commercialization optionality and licensing or distribution leverage over months.
Negative Factors
Revenue collapse
A drop to zero reported revenue signals a fundamental disruption to commercial execution or product availability. Absent sustainable revenue recovery, the business lacks operating scale to cover fixed costs, undermining any path to durable profitability over the next several months.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary product/IP
The company owns a proprietary chemistry platform and a marketed product (Avenova) with both consumer and eye‑care professional channels. This entrenched product/IP and multi‑channel go‑to‑market provide durable commercialization optionality and licensing or distribution leverage over months.
Read all positive factors
Stablecoin Development Corp (SDEV) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$43.40M
Dividend YieldN/A
Average Volume (3M)490.93K
Price to Earnings (P/E)―
Beta (1Y)1.90
Revenue Growth-74.73%
EPS Growth95.81%
CountryUS
Employees4
SectorFinancial
Sector Strength70
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)-5.73
Shares Outstanding26,625,029
10 Day Avg. Volume207,536
30 Day Avg. Volume490,928
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.32
Price to Sales (P/S)0.00
P/FCF Ratio-0.86
Enterprise Value/Market Cap0.83
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-258.69
Enterprise Value/Ebitda-4.86
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.9
Revenue Forecast (FY)$15.80M
Stablecoin Development Corp Business Overview & Revenue Model
Company Description
Stablecoin Development Corp. engages in the development and sales of scientifically-created and clinically-proven eyecare and skincare. Its products include Avenova, NeutroPhase and DERMAdoctor. The company was founded on January 19, 2000 and is h...
How the Company Makes Money
NovaBay has historically generated revenue primarily from product sales of Avenova and related eye-care offerings. The company’s revenue model is centered on (1) selling finished goods through commercial channels (including direct-to-consumer and ...
Stablecoin Development Corp Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
9
Very Negative
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 10.46M | 14.40M | 10.20M |
| Gross Profit | -140.00K | -341.00K | 6.08M | 7.78M | 6.51M |
| EBITDA | -7.45M | -7.04M | -3.75M | -7.20M | -8.74M |
| Net Income | -33.34M | -7.22M | -6.14M | -10.61M | -5.82M |
Balance Sheet | |||||
| Total Assets | 10.65M | 45.91M | 50.42M | 16.40M | 23.98M |
| Cash, Cash Equivalents and Short-Term Investments | 7.96M | 430.00K | 2.92M | 5.36M | 7.50M |
| Total Debt | 776.00K | 1.67M | 2.61M | 2.04M | 551.00K |
| Total Liabilities | 33.47M | 46.03M | 47.10M | 5.84M | 13.81M |
| Stockholders Equity | -22.83M | -129.00K | 3.31M | 10.55M | 10.17M |
Cash Flow | |||||
| Free Cash Flow | -8.43M | -7.50M | -4.28M | -6.77M | -9.24M |
| Operating Cash Flow | -8.43M | -7.50M | -4.26M | -6.65M | -9.19M |
| Investing Cash Flow | 0.00 | 0.00 | -19.00K | -112.00K | -12.04M |
| Financing Cash Flow | 4.62M | 1.50M | 1.91M | 4.63M | 16.79M |
Stablecoin Development Corp Technical Analysis
Negative
2.95
Price Trends
1.85
Negative
12.88
Negative
8.88
Negative
Market Momentum
-0.49
Negative
39.75
Neutral
14.97
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SDEV, the sentiment is Negative. The current price of 2.95 is above the 20-day moving average (MA) of 1.56, above the 50-day MA of 1.85, and below the 200-day MA of 8.88, indicating a bearish trend. The MACD of -0.49 indicates Negative momentum. The RSI at 39.75 is Neutral, neither overbought nor oversold. The STOCH value of 14.97 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SDEV.
Stablecoin Development Corp Risk Analysis
Stablecoin Development Corp disclosed 26 risk factors in its most recent earnings report. Stablecoin Development Corp reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Stablecoin Development Corp Peers Comparison
UnderperformOutperform
Sector (68)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
58 Neutral | $36.20M | -1.29 | -61.62% | ― | 123.59% | 86.82% | |
43 Neutral | $4.06M | -0.24 | -212.63% | ― | 106.81% | 85.91% | |
40 Underperform | $3.02M | ― | -248.01% | ― | ― | 54.48% | |
40 Underperform | $1.20M | -0.02 | 9999.00% | ― | -1.52% | 84.32% | |
38 Underperform | $43.40M | -0.07 | 1237.14% | ― | -74.73% | 95.81% |
* Financial Sector Average
SDEV
Stablecoin Development Corp
1.63
-0.19
-10.34%
SNGX
Soligenix
0.29
-1.67
-85.05%
JAGX
Jaguar Animal Health
3.00
-268.95
-98.90%
EVAX
Evaxion Biotech
4.34
2.85
191.28%
SPRC
SciSparc Ltd.
6.25
-60.30
-90.61%
SXTP
60 Degrees Pharmaceuticals, Inc.
1.54
-8.14
-84.09%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.